|
Shield Therapeutics PLC on Wednesday noted positive efficacy and tolerance results from in its phase three ferric maltol Fortis trial. The Newcastle, England-based commercial-stage pharmaceutical company said the Accrufer trial assessed doses of ferric metal in infants, children and adolescents suffering with iron deficiency anaemia. Data was presented on Monday this week at the American Association of Pediatrics National Conference in Colorado. Key findings included statistically and clinically significant haemoglobin improvements versus baseline, with Shield noting that no patient stopped the ferric maltol treatment due to an adverse event. It added that this compared to the ferrous sulfate arm, in which one person discontinued. Further, treatment-related adverse events were reported in 6.5% of patients with ferric maltol, compared to 13% treated with ferrous sulphate. Shares in the company rose 4.8% to 7.70 pence on Wednesday afternoon in London. ‘This first publication of results confirming the safety and effectiveness of ferric maltol treatment in children as young as 2 months is an important milestone for Shield to further the expansion of ACCRUFeR in this additional patient population who can benefit from a much needed safe and effective oral iron treatment,’ said Shield VP of Quality, RA and Clinical Development Jackie Mitchell. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
